<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0" 
  xmlns:dc="http://purl.org/dc/elements/1.1/"
  xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
  xmlns:admin="http://webns.net/mvcb/"
  xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">

<channel>
<title>In the Pipeline</title>
<link>/home/corante/public_html/pipeline/</link>
<description></description>
<dc:language>en-us</dc:language>
<dc:creator>derekb.lowe@gmail.com</dc:creator>
<dc:date>2013-06-17T11:18:51-05:00</dc:date>
<admin:generatorAgent rdf:resource="http://www.movabletype.org/?v=3.34" />
<sy:updatePeriod>hourly</sy:updatePeriod>
<sy:updateFrequency>1</sy:updateFrequency>
<sy:updateBase>2000-01-01T12:00+00:00</sy:updateBase>

<item>
<title>Pay-to-Delay: Not Necessarily Illegal, But Not Long For The World</title>
<link>http://pipeline.corante.com/archives/2013/06/17/paytodelay_not_necessarily_illegal_but_not_long_for_the_world.php</link>
<description>The Supreme Court has another ruling that affects the drug industry: FTC v. Actavis took up the question of &quot;pay to delay&quot;, the practice of paying generic companies to go away and not challenge a branded drug. Actavis was in...</description>
<guid isPermaLink="false">76484@/home/corante/public_html/pipeline/</guid>
<dc:subject>Regulatory Affairs</dc:subject>
<dc:date>2013-06-17T11:18:51-05:00</dc:date>
</item>
<item>
<title>The Supreme Court Rules on Myriad</title>
<link>http://pipeline.corante.com/archives/2013/06/13/the_supreme_court_rules_on_myriad.php</link>
<description>Just a little while ago, the Supreme Court issued a unanimous decision (rare these days) in the Myriad Genetics case. I summarized the state of play up until the most recent arguments here, and if you&apos;re just getting up to...</description>
<guid isPermaLink="false">76475@/home/corante/public_html/pipeline/</guid>
<dc:subject>Patents and IP</dc:subject>
<dc:date>2013-06-13T10:41:35-05:00</dc:date>
</item>
<item>
<title>Deuterated Drugs: An Obvious Idea?</title>
<link>http://pipeline.corante.com/archives/2013/06/10/deuterated_drugs_an_obvious_idea.php</link>
<description>Nature Medicine has an update on the deuterated drug landscape. There are several compounds in the clinic, and the time to the first marketed deuterium-containing drug is surely counting down. But, as mentioned at the end of that piece, another...</description>
<guid isPermaLink="false">76466@/home/corante/public_html/pipeline/</guid>
<dc:subject>Patents and IP</dc:subject>
<dc:date>2013-06-10T06:52:56-05:00</dc:date>
</item>
<item>
<title>Novartis Loses the Glivec Patent Fight in India</title>
<link>http://pipeline.corante.com/archives/2013/04/01/novartis_loses_the_glivec_patent_fight_in_india.php</link>
<description>This story is all over the news today, but it&apos;s my impression that most of the stories leave out crucial details. This is not just a big multinational drug company being put in its place by Indian courts, nor is...</description>
<guid isPermaLink="false">76317@/home/corante/public_html/pipeline/</guid>
<dc:subject>Patents and IP</dc:subject>
<dc:date>2013-04-01T11:20:55-05:00</dc:date>
</item>
<item>
<title>Standard of Care? Not So Fast, Not in the United Kingdom</title>
<link>http://pipeline.corante.com/archives/2013/02/26/standard_of_care_not_so_fast_not_in_the_united_kingdom.php</link>
<description>Did you know that in the UK, patent law says that using a competitor&apos;s compound as a comparison in a clinical trial is an infringement? I sure didn&apos;t. The government has realized that this rule is much stricter than most...</description>
<guid isPermaLink="false">76239@/home/corante/public_html/pipeline/</guid>
<dc:subject>Patents and IP</dc:subject>
<dc:date>2013-02-26T11:45:27-05:00</dc:date>
</item>
<item>
<title>Oops. We Didn&apos;t Mean to Publish That.</title>
<link>http://pipeline.corante.com/archives/2012/10/31/oops_we_didnt_mean_to_publish_that.php</link>
<description>Here&apos;s an interesting situation, courtesy of Retraction Watch - trying to pull back a paper because it disclosed something that was supposed to be the subject of your patent. Say the authors of the paper in the Korean Journal of...</description>
<guid isPermaLink="false">75974@/home/corante/public_html/pipeline/</guid>
<dc:subject>Patents and IP</dc:subject>
<dc:date>2012-10-31T10:44:22-05:00</dc:date>
</item>
<item>
<title>JQ1: Giving Up a Fortune?</title>
<link>http://pipeline.corante.com/archives/2012/10/30/jq1_giving_up_a_fortune.php</link>
<description>The Atlantic is out with a list of &quot;Brave Thinkers&quot;, and one of them is Jay Bradner at Harvard Medical School. He&apos;s on there for JQ1, a small-molecule bromodomain ligand that was reported in 2010. (I note, in passing, that...</description>
<guid isPermaLink="false">75970@/home/corante/public_html/pipeline/</guid>
<dc:subject>Patents and IP</dc:subject>
<dc:date>2012-10-30T08:48:57-05:00</dc:date>
</item>
<item>
<title>The American Chemical Society&apos;s Lawsuit Problem</title>
<link>http://pipeline.corante.com/archives/2012/09/19/the_american_chemical_societys_lawsuit_problem.php</link>
<description>Since we&apos;ve been talking about the ACS around here recently, I wanted to highlight a decision in a long-running court case the society has been involved in, American Chemical Society v. Leadscope. Rich Apodaca has a summary here of the...</description>
<guid isPermaLink="false">75872@/home/corante/public_html/pipeline/</guid>
<dc:subject>Chemical News</dc:subject>
<dc:date>2012-09-19T06:38:37-05:00</dc:date>
</item>
<item>
<title>The Myriad Gene Patent Case: Trickier Than You Might Think</title>
<link>http://pipeline.corante.com/archives/2012/08/17/the_myriad_gene_patent_case_trickier_than_you_might_think.php</link>
<description>All right, there&apos;s been another ruling in the Myriad gene patent case, involving genetic testing for the BRCA mutations in breast cancer. There&apos;s been a lot of coverage of this, but not all of it gets the details right. And...</description>
<guid isPermaLink="false">75820@/home/corante/public_html/pipeline/</guid>
<dc:subject>Patents and IP</dc:subject>
<dc:date>2012-08-17T06:59:35-05:00</dc:date>
</item>
<item>
<title>What Compound Are You Trying to Patent, Again?</title>
<link>http://pipeline.corante.com/archives/2012/06/18/what_compound_are_you_trying_to_patent_again.php</link>
<description>I sure hope that Sanofi doesn&apos;t really want to own these compounds in this recent patent filing. (Thanks to a reader at another company for sending this along!) But what are the odds of that, given that they went to...</description>
<guid isPermaLink="false">75705@/home/corante/public_html/pipeline/</guid>
<dc:subject>Patents and IP</dc:subject>
<dc:date>2012-06-18T08:35:21-05:00</dc:date>
</item>
<item>
<title>China&apos;s Compulsory Licensing</title>
<link>http://pipeline.corante.com/archives/2012/06/11/chinas_compulsory_licensing.php</link>
<description>The Chinese government recently amended its intellectual property law to allow for compulsory licensing. Similar measures are on the books in many other companies, and it&apos;s allowed under international patent law (WIPO) in cases of emergency or threats to public...</description>
<guid isPermaLink="false">75694@/home/corante/public_html/pipeline/</guid>
<dc:subject>Patents and IP</dc:subject>
<dc:date>2012-06-11T07:34:04-05:00</dc:date>
</item>
<item>
<title>Publishing Without Consent</title>
<link>http://pipeline.corante.com/archives/2012/05/24/publishing_without_consent.php</link>
<description>Here&apos;s a note on an ugly situation: when a post-doc publishes a paper without the permission of the principal investigator. Now, this is a fairly rare situation, but still not as rare as you might imagine - the article itself...</description>
<guid isPermaLink="false">75657@/home/corante/public_html/pipeline/</guid>
<dc:subject>The Scientific Literature</dc:subject>
<dc:date>2012-05-24T06:15:16-05:00</dc:date>
</item>
<item>
<title>A Long-Delayed COX2 Issue Gets Settled - For $450 Million?</title>
<link>http://pipeline.corante.com/archives/2012/05/03/a_longdelayed_cox2_issue_gets_settled_for_450_million.php</link>
<description>Has the last shot been fired, very quietly, in the COX-2 discovery wars? Here&apos;s the background, in which some readers of this site have probably participated at various times. Once it was worked out that the nonsteroidal antiinflammatory drugs (aspirin,...</description>
<guid isPermaLink="false">75610@/home/corante/public_html/pipeline/</guid>
<dc:subject>Drug Industry History</dc:subject>
<dc:date>2012-05-03T07:07:10-05:00</dc:date>
</item>
<item>
<title>The Supreme Court Makes Me Smile</title>
<link>http://pipeline.corante.com/archives/2012/03/21/the_supreme_court_makes_me_smile.php</link>
<description>I wrote here about the Mayo v. Prometheus case, which dealt with patents on the use of thiopurines for autoimmune therapy. But the patents didn&apos;t claim any thiopurine drugs themselves. Or their specific use for autoimmune therapy. Or vehicles to...</description>
<guid isPermaLink="false">75538@/home/corante/public_html/pipeline/</guid>
<dc:subject>Patents and IP</dc:subject>
<dc:date>2012-03-21T07:33:27-05:00</dc:date>
</item>
<item>
<title>Department of Lots of Nerve (Patent Applications Desk)</title>
<link>http://pipeline.corante.com/archives/2012/03/05/department_of_lots_of_nerve_patent_applications_desk.php</link>
<description>When you file a patent application, there are plenty of things that the PTO wants you to include. One of the big ones is prior art: you&apos;re supposed to disclose all the relevant inventions close to yours that you&apos;re aware...</description>
<guid isPermaLink="false">75500@/home/corante/public_html/pipeline/</guid>
<dc:subject>Patents and IP</dc:subject>
<dc:date>2012-03-05T12:49:01-05:00</dc:date>
</item>


</channel>
</rss>